Spots Global Cancer Trial Database for TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Official Title: A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Study ID: NCT03032484
Conditions
Study Description
Brief Summary: Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
Detailed Description: Eligible patients will be randomized into 2 separate arms: * Arm number one will receive Bevacizumab every 2 weeks in combination with TVB-2640 from day 1 until day 28 of the first cycle. * Arm number two will receive Bevacizumab alone every 2 weeks, from on days 1 and 15 of the first until day 28 of the first cycle. * MR-Spectroscopy will be obtained on all patients (both arms) at day 28 of first cycle. * Starting on cycle 2 day 1, all patients will converge to a single arm and will continue to receive bevacizumab every 2 weeks in combination with TVB-2640. Every cycle will last 28 days.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States
Contact Details
Name: Andrew Brenner
Affiliation: UT Health San Antonio
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
